ClinicalTrials.gg
CompletedNCT04552470Updated Mar 11, 2022Results posted

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

A Phase 1 interventional study of Placebo and PF-06882961 in Type 2 Diabetes Mellitus, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.

Enrollment
49th of 79
37 · median 50
Started
2020
with 1 other
Phase 1
47 of 80
none open now
Registered
71st of 80
by date

Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 49th largest by enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2020, is one of 47 in phase 1, and was the 71st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Diabetes Mellitus, Type 2 by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double blind (sponsor open), parallel, placebo controlled, twice daily oral dosing study of PF 06882961 in adult Japanese participants with T2DM inadequately controlled on diet and exercise alone.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with T2DM who are treated with diet and exercise
  • greater than or equal to 7% and less than or equal to 10.5%
  • Total body weight >50 kg (110 lb) with 22.5 to 45.4 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Diagnosis of Type 1 diabetes
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or within 6 months of screening
  • Any not considered cured
  • Personal or family history of MTC or MEN2, or participants with suspected MTC
  • Acute pancreatitis or history of chronic pancreatitis
  • Symptomatic gallbladder disease
  • Known medical history of active proliferative retinopathy and/or macular edema
  • Known history of , , or syphilis
  • Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
  • abnormalities
  • Positive urine drug test
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    PF-06882961 40 mg

    Participants will be titrated up to 2 weeks to reach desired dose level

    Drug: PF-06882961

  • Experimental
    PF-06882961 80 mg

    Participants will be titrated up to 4 weeks to reach desired dose level

    Drug: PF-06882961

  • Experimental
    PF-06882961 120 mg

    Participants will be titrated up to 6 weeks to reach desired dose level

    Drug: PF-06882961

Interventions

  • DrugPlacebo

    3 matching placebo tablets taken twice a day (BID)

  • Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment emergent AEs were events between first dose of study drug and approximately 4 weeks after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.

    Time frame: Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)

  2. Number of Participants With Clinical Laboratory Abnormalities

    Leukocytes (10\^9/liter \[L\]) bilirubin (micromol/L), glucose (millimoles \[mmol\]/L), triacylglycerol lipase (microkatals \[microkat\]/L): greater than (\>) 1.5\*upper limit normal (ULN); activated partial thromboplastin time (s): 1.1\*ULN; HDL cholesterol (mmol/L), thyroid stimulating hormone (TSH) (milliunits \[mU\]/L): less than (\<) 0.8\*lower limit normal (LLN); LDL cholesterol (mmol/L), urate (mmol/L): \>1.2\*ULN; triglycerides: \>1.3\*ULN; aspartate aminotransferase (microkat/L), alanine aminotransferase (microkat/L), gamma glutamyl transferase (microkat/L): \>3.0\*ULN; cholesterol (mmol/L): \>1.3\*ULN; urine glucose, ketones urine protein, urine hemoglobin, urobilinogen, nitrite, leukocyte esterase: greater than or equal to (\>=) 1; granular casts, hyaline casts: \>1.

    Time frame: Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)

  3. Number of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline

    Supine systolic blood pressure (SBP) measured in millimeter of mercury (mmHg) had following categories: minimum of absolute SBP \<90 mmHg, maximum of SBP \>=30 mmHg decrease from baseline and maximum of SBP \>=30 mmHg increase from baseline. Supine diastolic blood pressure (DBP) measured in mmHg had following categories: minimum of absolute DBP \<50 mmHg, maximum of DBP \>20 mmHg decrease from baseline and maximum of DBP \>=20 mmHg increase from baseline. Supine pulse rate measured in beats per minute (BPM) had following categories: minimum of absolute supine pulse rate \<40 BPM and maximum of absolute supine pulse rate \>120 BPM. Baseline was defined as the time-matched value from the average of the triplicate recordings on Day -1.

    Time frame: Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)

  4. Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline

    PR interval had following categories: maximum absolute PR interval \>=300 milliseconds (msec); when baseline PR interval \>200 msec and maximum increase from baseline in PR interval \>=25 percent; when baseline PR interval less than or equal to (\<=) 200 msec and maximum increase from baseline in PR interval \>=50 percent. QRS interval had following categories: maximum absolute QRS interval \>=140 msec; maximum increase from baseline in QRS interval \>=50 percent. QTC interval with Frederica's correction (QTCF) had following categories: absolute QTCF interval \>450 msec to \<=480 msec; absolute QTCF interval \>480 msec to \<=500 msec; absolute QTCF interval \>500 msec; QTCF interval increase from baseline \>=30 msec to \<=60 msec; QTCF interval increase from baseline \>60 msec.

    Time frame: Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)

Secondary outcomes

  1. Area Under the Plasma Concentration-time Profile From Zero to Time 24 Hours (AUC24) of PF-06882961

    AUC24= Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1 and 56

  2. Maximum Plasma Concentration (Cmax) Observed of PF-06882961

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06882961

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56

  4. Terminal Phase Half-Life (t1/2) of PF-06882961

    t1/2 was calculated as loge (2) per kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56

07

Results

Posted Mar 11, 2022

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Started91099
Completed91099
Not completed0000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment emergent AEs were events between first dose of study drug and approximately 4 weeks after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.

Time frame:
Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Participants with AEs3799
Participants with SAEs0000
PrimaryNumber of Participants With Clinical Laboratory Abnormalities

Leukocytes (10\^9/liter \[L\]) bilirubin (micromol/L), glucose (millimoles \[mmol\]/L), triacylglycerol lipase (microkatals \[microkat\]/L): greater than (\>) 1.5\*upper limit normal (ULN); activated partial thromboplastin time (s): 1.1\*ULN; HDL cholesterol (mmol/L), thyroid stimulating hormone (TSH) (milliunits \[mU\]/L): less than (\<) 0.8\*lower limit normal (LLN); LDL cholesterol (mmol/L), urate (mmol/L): \>1.2\*ULN; triglycerides: \>1.3\*ULN; aspartate aminotransferase (microkat/L), alanine aminotransferase (microkat/L), gamma glutamyl transferase (microkat/L): \>3.0\*ULN; cholesterol (mmol/L): \>1.3\*ULN; urine glucose, ketones urine protein, urine hemoglobin, urobilinogen, nitrite, leukocyte esterase: greater than or equal to (\>=) 1; granular casts, hyaline casts: \>1.

Time frame:
Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities
ParticipantsPlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Number of Participants With Clinical Laboratory Abnormalities91089
PrimaryNumber of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline

Supine systolic blood pressure (SBP) measured in millimeter of mercury (mmHg) had following categories: minimum of absolute SBP \<90 mmHg, maximum of SBP \>=30 mmHg decrease from baseline and maximum of SBP \>=30 mmHg increase from baseline. Supine diastolic blood pressure (DBP) measured in mmHg had following categories: minimum of absolute DBP \<50 mmHg, maximum of DBP \>20 mmHg decrease from baseline and maximum of DBP \>=20 mmHg increase from baseline. Supine pulse rate measured in beats per minute (BPM) had following categories: minimum of absolute supine pulse rate \<40 BPM and maximum of absolute supine pulse rate \>120 BPM. Baseline was defined as the time-matched value from the average of the triplicate recordings on Day -1.

Time frame:
Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)
Reported as:
Count of participants · Participants
Number of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline
ParticipantsPlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Minimum of absolute SBP <90 mmHg0000
Maximum of SBP >=30 mmHg decrease1001
Maximum of SBP >=30 mmHg increase3232
Minimum of absolute DBP <50 mmHg0000
Maximum of DBP >=20 mmHg decrease0000
Maximum of DBP >=20 mmHg increase1233
Minimum of absolute pulse rate <40 BPM0000
Maximum of absolute pulse rate >120 BPM0000
PrimaryNumber of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline

PR interval had following categories: maximum absolute PR interval \>=300 milliseconds (msec); when baseline PR interval \>200 msec and maximum increase from baseline in PR interval \>=25 percent; when baseline PR interval less than or equal to (\<=) 200 msec and maximum increase from baseline in PR interval \>=50 percent. QRS interval had following categories: maximum absolute QRS interval \>=140 msec; maximum increase from baseline in QRS interval \>=50 percent. QTC interval with Frederica's correction (QTCF) had following categories: absolute QTCF interval \>450 msec to \<=480 msec; absolute QTCF interval \>480 msec to \<=500 msec; absolute QTCF interval \>500 msec; QTCF interval increase from baseline \>=30 msec to \<=60 msec; QTCF interval increase from baseline \>60 msec.

Time frame:
Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)
Reported as:
Count of participants · Participants
Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline
ParticipantsPlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Maximum absolute PR >=300 msec0000
Baseline PR >200 msec and maximum increase in PR >=25%0000
Baseline PR <=200 msec and maximum increase in PR >=50%0000
Maximum absolute QRS >=140 msec0000
Maximum increase in QRS >=50%0000
Absolute QTCF interval >450 msec to <=480 msec1011
Absolute QTCF interval >480 msec to <=500 msec0000
Absolute QTCF >500 msec0000
QTCF increase >=30 msec to <=60 msec0000
QTCF increase >60 msec0000
SecondaryArea Under the Plasma Concentration-time Profile From Zero to Time 24 Hours (AUC24) of PF-06882961

AUC24= Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1 and 56
Reported as:
Geometric mean · Nanogram*hour per milliliter
Area Under the Plasma Concentration-time Profile From Zero to Time 24 Hours (AUC24) of PF-06882961
Nanogram*hour per milliliterPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Day 1414.4 ± 58500.3 ± 58484.5 ± 73
Day 562424 ± 454691 ± 756953 ± 148
SecondaryMaximum Plasma Concentration (Cmax) Observed of PF-06882961
Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Plasma Concentration (Cmax) Observed of PF-06882961
Nanogram per milliliterPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Day 132.83 ± 5545.89 ± 5239.35 ± 80
Day 56206.1 ± 54352.2 ± 75551.7 ± 153
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06882961
Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
Reported as:
Median · Hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06882961
HoursPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Day 112.0 (2.00 to 23.8)12.0 (1.00 to 12.0)12.0 (1.00 to 14.0)
Day 5612.0 (6.00 to 13.8)12.9 (2.00 to 36.0)12.0 (0.000 to 13.8)
SecondaryTerminal Phase Half-Life (t1/2) of PF-06882961

t1/2 was calculated as loge (2) per kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
Reported as:
Mean · Hours
Terminal Phase Half-Life (t1/2) of PF-06882961
HoursPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
Terminal Phase Half-Life (t1/2) of PF-068829616.373 ± 1.74045.543 ± 0.308275.300 ± 0.80594

Adverse events

Collected over Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/9 (0%)0/9 (0%)3/9 (33.3%)
PF-06882961 40 mg0/10 (0%)0/10 (0%)7/10 (70%)
PF-06882961 80 mg0/9 (0%)0/9 (0%)9/9 (100%)
PF-06882961 120 mg0/9 (0%)0/9 (0%)9/9 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mg
NauseaGastrointestinal disorders0/96/108/94/9
VomitingGastrointestinal disorders0/95/106/95/9
Abdominal discomfortGastrointestinal disorders0/94/104/95/9
DiarrhoeaGastrointestinal disorders0/91/102/91/9
HeadacheNervous system disorders1/92/101/90/9
Abdominal pain upperGastrointestinal disorders0/90/101/90/9
Dental cariesGastrointestinal disorders1/90/100/91/9
StomatitisGastrointestinal disorders0/90/101/90/9
InfluenzaInfections and infestations0/90/100/91/9
Lipase increasedInvestigations1/90/100/90/9

Baseline characteristics

Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)PlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mgTotal
Mean58.6 ± 8.7555.9 ± 10.0458.0 ± 6.6950.7 ± 7.5055.8 ± 8.62
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mgTotal
Female12115
Male888832
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mgTotal
Hispanic or Latino00000
Not Hispanic or Latino9109937
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPF-06882961 40 mgPF-06882961 80 mgPF-06882961 120 mgTotal
American Indian or Alaska Native00000
Asian9109937
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • P-one clinic, Keikokai medical corporation
    Hachioji, Tokyo 192-0071, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2021, 4 months.

Results were first posted in Mar 2022, 11 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Sep 17, 2020
StartActual
Oct 26, 2020
Primary completionActual
Mar 25, 2021
CompletionActual
Mar 25, 2021
Results first posted
Mar 11, 2022
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04552470
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 17, 2020
Start date
Oct 26, 2020
Primary completion
Mar 25, 2021
Completion
Mar 25, 2021
Results posted
Mar 11, 2022
Last update
Mar 11, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion